Articles by Christopher A. Flask in JoVE
Vivo दोहरी सब्सट्रेट bioluminescent इमेजिंग में Michael K. Wendt1, Joseph Molter1, Christopher A. Flask1, William P. Schiemann1 1Case Comprehensive Cancer Center, Case Western Reserve University हम साथ साथ निर्माण करने के लिए, कल्पना, और दोनों जुगनू और renilla luciferase एंजाइमों की bioluminescent प्रतिक्रियाओं metastatic स्तन कैंसर की कोशिकाओं में उनके विकास और मेटास्टेसिस के दौरान व्यक्त यों विधियों का वर्णन
Other articles by Christopher A. Flask on PubMed
Magnetic Resonance Imaging of Multifunctional Pluronic Stabilized Iron-oxide Nanoparticles in Tumor-bearing Mice Biomaterials. Dec, 2009 | Pubmed ID: 19765817 We are investigating the magnetic resonance imaging characteristics of magnetic nanoparticles (MNPs) that consist of an iron-oxide magnetic core coated with oleic acid (OA), then stabilized with a pluronic or tetronic block copolymer. Since pluronics and tetronics vary structurally, and also in the ratio of hydrophobic (poly[propylene oxide]) and hydrophilic (poly[ethylene oxide]) segments in the polymer chain and in molecular weight, it was hypothesized that their anchoring to the OA coating around the magnetic core could significantly influence the physical properties of MNPs, their interactions with biological environment following intravenous administration, and ability to localize to tumors. The amount of block copolymer associated with MNPs was seen to depend upon their molecular structures and influence the characteristics of MNPs. Pluronic F127-modified MNPs demonstrated sustained and enhanced contrast in the whole tumor, whereas that of Feridex IV was transient and confined to the tumor periphery. In conclusion, our pluronic F127-coated MNPs, which can also be loaded with anticancer agents for drug delivery, can be developed as an effective cancer theranostic agent, i.e. an agent with combined drug delivery and imaging properties.
A Novel PET Marker for in Vivo Quantification of Myelination Bioorganic & Medicinal Chemistry. Dec, 2010 | Pubmed ID: 21071233 C-11-labeled N-methyl-4,4'-diaminostilbene ([(11)C]MeDAS) was synthesized and evaluated as a novel radiotracer for in vivo microPET imaging of myelination. [(11)C]MeDAS exhibits optimal lipophilicity for brain uptake with a logP(oct) value of 2.25. Both in vitro and ex vivo staining exhibited MeDAS accumulation in myelinated regions such as corpus callosum and striatum. The corpus callosum region visualized by MeDAS is much larger in the hypermyelinated Plp-Akt-DD mouse brain than in the wild-type mouse brain, a pattern that was also consistently observed in Black-Gold or MBP antibody staining. Ex vivo autoradiography demonstrated that [(11)C]MeDAS readily entered the mouse brain and selectively labeled myelinated regions with high specificity. Biodistribution studies showed abundant initial brain uptake of [(11)C]MeDAS with 2.56% injected dose/whole brain at 5 min post injection and prolonged retention in the brain with 1.37% injected dose/whole brain at 60 min post injection. An in vivo pharmacokinetic profile of [(11)C]MeDAS was quantitatively analyzed through a microPET study in an Plp-Akt-DD hypermyelinated mouse model. MicroPET studies showed that [(11)C]MeDAS exhibited a pharmacokinetic profile that readily correlates the radioactivity concentration to the level of myelination in the brain. These studies suggest that MeDAS is a sensitive myelin probe that provides a direct means to detect myelin changes in the brain. Thus, it can be used as a myelin-imaging marker to monitor myelin pathology in vivo.
Autoimmune Mediated Regulation of Ovarian Tumor Growth Gynecologic Oncology. Jan, 2012 | Pubmed ID: 22004903 An immune response sufficient to induce organ failure may provide protection and therapy against tumors derived from the targeted organ particularly when removal or ablation of the organ is part of the standard therapy and does not threaten survival. We have previously shown that a targeted immune response directed against the ovarian-specific protein, inhibin-Î±, causes ovarian failure. Here we determined whether inhibin-Î± autoimmunity is effective in both prevention and treatment of ovarian tumors.